Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the LEAP-002 basket study investigating lenvatinib, a tyrosine kinase inhibitor, in combination with pembrolizumab in patients with microsatellite stable colorectal cancer (CRC). Dr Kim evaluates the results of this study in the context of checkpoint inhibitor blockade strategies assessed in microsatellite stable CRC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
